Physician profile
Keith L Lee
NPI 1699766188
$9,771.09
in general payments reported to CMS, 2019-2025
42 companies · $2,147 in 2025
The $2,147 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,273 · 2020: $218 · 2022: $1,107 · 2023: $2,854 · 2024: $2,172 · 2025: $2,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,172.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,388.11 | 2019-2025 | Farxiga, Airsupra, Evusheld |
| Lilly USA, LLC | $1,219.27 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,197.51 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Glaxosmithkline, LLC. | $1,089.70 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $680.18 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $674.46 | 2023-2025 | |
| Amgen INC. | $568.81 | 2022-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $506.69 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $341.36 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Janssen Pharmaceuticals, INC | $215.93 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $202.58 | 2019-2022 | |
| Exact Sciences Corporation | $187.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Gilead Sciences, INC. | $171.15 | 2019-2025 | |
| Abbott Laboratories | $169.86 | 2024-2025 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $139.47 | 2022-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.